Comprehensive safety assessment of ribociclib: A real‐world analysis using the FDA Adverse Event Reporting System (FAERS) database
Our study provides real-world safety data on post-marketing surveillance and highlights potential new and unexpected AE signals during ribociclib treatment.
Authors
- Bin Zhao (ORCID: https://orcid.org/0000-0002-8165-3315)
- Xiangning Chen (ORCID: https://orcid.org/0000-0002-9011-4946)
- Shu Liu (ORCID: https://orcid.org/0009-0000-2914-1091)
- Yue Wang (ORCID: https://orcid.org/0009-0002-8013-780X)
- Lan Luo (ORCID: https://orcid.org/0000-0002-3400-4742)
- Yumei Fu
Institutions
- Wuhan Polytechnic University (CN)
- Guiyang Medical University (CN)
- Sun Yat-sen University (CN)
- Xiamen University (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Xiamen Tobacco Industry (China) (CN)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/bcp.70265
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52